Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status

被引:1
作者
Korsholm, Karen Smith [1 ]
Andersen, Peter Lawtz [1 ]
Christensen, Dennis [1 ]
机构
[1] Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark
关键词
adjuvants; animal models; cationic liposomes; clinical trials; vaccines; DIOCTADECYL AMMONIUM-BROMIDE; LEISHMANIA-DONOVANI ANTIGENS; TUBERCULOSIS SUBUNIT VACCINE; INDUCE PROTECTIVE IMMUNITY; PROTEIN-BASED VACCINE; LONG-TERM PROTECTION; DNA COMPLEXES CLDC; T-CELL ANTIGENS; DENDRITIC CELLS; VISCERAL LEISHMANIASIS;
D O I
10.1586/ERV.12.22
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cationic liposome formulations can function as efficient vaccine adjuvants. However, due to the highly diverse nature of lipids, cationic liposomes have different physical-chemical characteristics that influence their adjuvant mechanisms and their relevance for use in different vaccines. These characteristics can be further manipulated by incorporation of additional lipids or stabilizers, and inclusion of carefully selected immunostimulators is a feasible strategy when tailoring cationic liposomal adjuvants for specific disease targets. Thus, cationic liposomes present a plasticity, which makes them promising adjuvants for future vaccines. This versatility has also led to a vast amount of literature on different experimental liposomal formulations in combination with a wide range of immunostimulators. Here, we have compiled information about the animal challenge models and administration routes that have been used to study vaccine adjuvants based on cationic liposomes and provide an overview of the applicability, progress and clinical status of cationic liposomal vaccine adjuvants.
引用
收藏
页码:561 / 577
页数:17
相关论文
共 145 条
[31]   Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol [J].
Devaraj, GN ;
Parakh, SR ;
Devraj, R ;
Apte, SS ;
Rao, BR ;
Rambhau, D .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2002, 251 (02) :360-365
[32]   Synergistic effect of bacillus Calmette Guerin and a tuberculosis subunit vaccine in cationic liposomes: Increased immunogenicity and protection [J].
Dietrich, Jes ;
Billeskov, Rolf ;
Doherty, T. Mark ;
Andersen, Peter .
JOURNAL OF IMMUNOLOGY, 2007, 178 (06) :3721-3730
[33]   Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice [J].
Dong, Libo ;
Liu, Feng ;
Fairman, Jeffery ;
Hong, David K. ;
Lewis, David B. ;
Monath, Thomas ;
Warner, John F. ;
Belser, Jessica A. ;
Patel, Jenish ;
Hancock, Kathy ;
Katz, Jacqueline M. ;
Lu, Xiuhua .
VACCINE, 2012, 30 (02) :254-264
[34]   Use of defined TLR ligands as adjuvants within human vaccines [J].
Duthie, Malcolm S. ;
Windish, Hillarie Plessner ;
Fox, Christopher B. ;
Reed, Steven G. .
IMMUNOLOGICAL REVIEWS, 2011, 239 :178-196
[35]   A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity [J].
Even-Or, Orli ;
Joseph, Aviva ;
Itskovitz-Cooper, Noga ;
Samira, Sarit ;
Rochlin, Eli ;
Eliyahu, Hagit ;
Goldwaser, Itzik ;
Balasingam, Shobana ;
Mann, Alex J. ;
Lambkin-Williams, Rob ;
Kedar, Eli ;
Barenholz, Yechezkel .
VACCINE, 2011, 29 (13) :2474-2486
[36]   Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine [J].
Even-Or, Orli ;
Samira, Sarit ;
Rochlin, Eli ;
Balasingam, Shobana ;
Mann, Alex J. ;
Lambkin-Williams, Rob ;
Spira, Jack ;
Goldwaser, Itzhak ;
Ellis, Ronald ;
Barenholz, Yechezkel .
VACCINE, 2010, 28 (39) :6527-6541
[37]   DNA vaccination by immersion and ultrasound to trout viral haemorrhagic septicaemia virus [J].
Fernandez-Alonso, M ;
Rocha, A ;
Coll, JM .
VACCINE, 2001, 19 (23-24) :3067-3075
[38]   Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition [J].
Foged, C ;
Arigita, C ;
Sundblad, A ;
Jiskoot, W ;
Storm, G ;
Frokjaer, S .
VACCINE, 2004, 22 (15-16) :1903-1913
[39]   Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 [J].
Fomsgaard, Anders ;
Karlsson, Ingrid ;
Gram, Gregers ;
Schou, Christian ;
Tang, Sheila ;
Bang, Peter ;
Kromann, Ingrid ;
Andersen, Peter ;
Andreasen, Lars Vibe .
VACCINE, 2011, 29 (40) :7067-7074
[40]  
Franke ED, 1997, J IMMUNOL, V159, P3424